Overview

• Neuralink has received Health Canada's approval to conduct its CAN-PRIME clinical trial, the company's first human trial outside the United States.
• The trial will be conducted at Toronto Western Hospital, focusing on patients with quadriplegia caused by ALS or spinal cord injuries.
• The implant uses over 1,000 electrodes to interpret neural activity, enabling participants to control devices like computers and smartphones through thought alone.
• Previous trials in the U.S. faced challenges, including technical issues with electrode threads, but adjustments have been made for subsequent patients.
• Neuralink plans to use the trial results to refine its technology, which could eventually expand to treat other conditions such as blindness or even augment memory in healthy individuals.